Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARMEN CD 305 induction study of ontamalimab in moderate to severe Crohn's disease
2017-000575-88Phase 3Unknown
- Sponsor
- Takeda
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing ontamalimab induction with placebo induction (2 arms). Status: unknown.
02
Drugs
ontamalimab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2017-000575-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000575-88.